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ABSTRACT Given the limitations of current antileishmanial drugs and the utility of
oral combination therapy for other infections, developing an oral combination against
visceral leishmaniasis should be a high priority. In vitro combination studies with
DB766 and antifungal azoles against intracellular Leishmania donovani showed that
posaconazole and ketoconazole, but not fluconazole, enhanced DB766 potency.
Pharmacokinetic analysis of DB766-azole combinations in uninfected Swiss Webster
mice revealed that DB766 exposure was increased by higher posaconazole and keto-
conazole doses, while DB766 decreased ketoconazole exposure. In L. donovani-
infected BALB/c mice, DB766-posaconazole combinations given orally for 5 days
were more effective than DB766 or posaconazole alone. For example, 81%  1%
(means  standard errors) inhibition of liver parasite burden was observed for 37.5
mg/kg of body weight DB766 plus 15 mg/kg posaconazole, while 37.5 mg/kg DB766
and 15 mg/kg posaconazole administered as monotherapy gave 40%  5% and
21%  3% inhibition, respectively. Combination index (CI) analysis indicated that
synergy or moderate synergy was observed in six of nine combined dose groups,
while the other three were nearly additive. Liver concentrations of DB766 and
posaconazole increased in almost all combination groups compared to mono-
therapy groups, although many increases were not statistically significant. For
DB766-ketoconazole combinations evaluated in this model, two were antagonis-
tic, one displayed synergy, and one was nearly additive. These data indicate that
the efficacy of DB766-posaconazole and DB766-ketoconazole combinations in
vivo is influenced in part by the pharmacokinetics of the combination, and that
the former combination deserves further consideration in developing new treat-
ment strategies against visceral leishmaniasis.
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As the second-most deadly vector-borne parasitic disease, visceral leishmaniasis (VL)remains a major public health problem in several developing regions. The current
treatment of VL with pentavalent antimonials, amphotericin B (either as a deoxycholate
or liposomal formulation), paromomycin, and miltefosine is inadequate. These drugs
are either parenteral (antimonials, amphotericin B formulations, and paromomycin),
display significant toxicities (antimonials, amphotericin B deoxycholate, and miltefos-
ine), or require long courses of administration (antimonials, amphotericin B deoxy-
cholate, paromomycin, and miltefosine) (1). Combination therapy is a useful approach
in treating infections because the doses of individual compounds can frequently be
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lowered, resistance to individual components is minimized, and the duration of therapy
is often shortened. Considering the success of oral drug combinations for other
infectious diseases, such as tuberculosis and malaria, development of such a combi-
nation for VL would be a significant advance in VL treatment that would aid control/
elimination efforts.
We previously showed that arylimidamides (AIAs) possess potent in vitro antileish-
manial activity and good in vivo efficacy in rodent VL models. Through in vitro and in
vivo testing of AIAs, 2,5-bis[2-(2-i-propoxy)-4-(2-pyridylimino) aminophenyl]furan hy-
drochloride (DB766; key chemical structures are given in Fig. 1) was identified as the
most promising member of this class (2). DB766 exhibits 50% inhibitory concentrations
(IC50s) below 0.10 M against intracellular Leishmania donovani, L. amazonensis, and L.
major, is active in both murine and hamster models of L. donovani infection when given
orally, is not mutagenic in an Ames assay, and does not increase liver or kidney enzyme
levels when given at 100 mg/kg of body weight/day for five consecutive days in a
repeat-dose toxicity study in mice (2). Although it possesses many favorable qualities as
an antileishmanial candidate, DB766 does not display the therapeutic index needed
to progress further for development as monotherapy against VL. While many other
bis-AIAs have been synthesized, none are superior to DB766 (3–6). As part of an
investigation into the mechanism of action of DB766, L. donovani axenic amastigotes
resistant to this compound were raised through DB766 pressure in culture. The
resultant DB766-resistant parasites were hypersensitive to the azole antifungal drugs
posaconazole and ketoconazole, decreased expression of the protein CYP5122A1 was
observed in the resistant parasites, and synergy was reported between DB766 and
posaconazole against L. donovani -lactamase-expressing parasites in an intracellular
assay (7). CYP5122A1 is a novel cytochrome P450 essential for L. donovani survival that
plays an unknown role in ergosterol biosynthesis in Leishmania (8), implicating sterol
metabolism in the mechanism of action of DB766. Considering that these azole
antifungals are orally available and have shown various degrees of antileishmanial
efficacy when used in the clinic (9–11), in vitro interactions between DB766 and the oral
azole antifungal agents posaconazole, ketoconazole, and fluconazole (Fig. 1 shows
relevant chemical structures) have been investigated against intracellular L. donovani
using a high-content assay. The in vivo pharmacokinetics and antileishmanial efficacy of
DB766-posaconazole and DB766-ketoconazole combinations also have been deter-
mined in mouse models. The results presented here reveal the importance of pharma-
cokinetic considerations on the in vivo efficacy of these combinations.
RESULTS
Development of a high-content assay for intracellular L. donovani. Previous
work in our laboratory made use of both microscopic enumeration (2) and parasites
expressing a -lactamase gene (12, 13) for the evaluation of compounds for activity
FIG 1 Structures of DB766, posaconazole, ketoconazole, and fluconazole.
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against intracellular L. donovani. Since microscopic enumeration is too tedious for
routine evaluation of compounds and their combinations and because our -lactamase
parasites no longer reliably express this reporter gene, a high-content assay for
intracellular L. donovani (see Fig. S1 in the supplemental material) was developed based
on previously reported image-based assays (14, 15). Employing overnight infection of
macrophages as done previously to validate the assay, the Z= factor (16) for the infected
versus uninfected controls was 0.74  0.03 (means  standard errors; n  6). In these
assays, the IC50 for amphotericin B (AMB) was 0.046  0.002 M (n  6), while the IC50
for DB766 was 0.019  0.001 M (n  3). Infected and uninfected control values along
with a dose-response curve for AMB from a representative experiment are shown in Fig.
S2. These values, obtained by high-content image analysis, are comparable with our
previously reported IC50s for AMB and DB766 against intracellular L. donovani. For AMB,
we previously reported IC50s of 0.066 M (2) and 0.041 M (13), as determined by
microscopy and with the -lactamase-expressing strain, respectively, while for DB766,
we reported an IC50 of 0.036 M (2) as determined by microscopy. Intracellular parasite
burden was also analyzed, and the number of parasites per macrophage in untreated
controls was static for the duration of the experiment (Table S1).
Analysis of the interaction between DB766 and posaconazole using fixed-ratio
dilutions. A synergistic interaction was previously reported between DB766 and po-
saconazole against intracellular L. donovani using parasites expressing a -lactamase
gene (7). The interaction between DB766 and posaconazole was examined using the
high-content assay described above. While posaconazole decreased intracellular para-
site burden as measured in the high-content assay, it did not clear intracellular L.
donovani from the macrophages, and precise IC50s were difficult to determine with
posaconazole because of its low in vitro selectivity for the parasites. When macrophages
were infected for 4 to 6 h prior to washing in an attempt to limit intracellular parasite
burden, IC50s for DB766 were 0.020  0.006 M in four such experiments (means 
standard errors). An antiparasitic effect was observed with posaconazole in each of
these experiments, but precise IC50s for this azole could be calculated in only two of the
four experiments due to the toxicity of this azole on the host cells. Given the mean FIC
(sum of the fractional inhibitory concentration) values for the DB766-posaconazole
combination in experiments where IC50s could be determined for posaconazole (1.2 for
both) and the FIC values for DB766 in the experiments in which IC50s for posaconazole
could not be calculated (ranging from 0.63 to 0.97 at different DB766/posaconazole
ratios), the interaction between DB766 and posaconazole against L. donovani is char-
acterized as indifferent by the fixed-ratio method using the intracellular high-content
assay. The results of these individual experiments are summarized in tabular form in
Table S2.
In vitro combinations of DB766 with posaconazole, ketoconazole, and flucona-
zole. With the goal of identifying oral combinations for in vivo evaluation as antileish-
manial candidates, the effect of three orally available azole antifungals was examined
in combination with DB766. It was difficult to determine an IC50 for ketoconazole in the
intracellular assay for the same reasons described above for posaconazole, while
fluconazole displayed little activity against intracellular L. donovani in vitro. Thus, the
effect of fixed concentrations of these azole drugs on the IC50 of DB766 was determined
(Fig. 2). In each case, the fixed concentrations of the azole drugs posaconazole,
ketoconazole, and fluconazole, included with serial dilutions of DB766, resulted in
50% inhibition of parasite burden when used alone (representative dose-response
scatter plots for these azoles in the intracellular L. donovani assay are provided in Fig.
S3). Inclusion of 4 M posaconazole or ketoconazole at 20 M, 15 M, and 10 M
resulted in a significant reduction of the DB766 IC50 (P  0.01), while addition of 2 M
posaconazole or fluconazole at 20 M and 40 M did not have a significant effect on
the IC50 of DB766 against intracellular L. donovani.
Efficacy of posaconazole and ketoconazole in the murine visceral leishmaniasis
model. Since both posaconazole and ketoconazole enhanced the activity of DB766
against intracellular L. donovani in vitro, combinations between these two azoles and
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DB766 were evaluated in vivo. Prior to testing these combinations in mice, the maxi-
mum tolerated doses and the efficacy of posaconazole and ketoconazole were deter-
mined in the same murine models that were to be used to assess the combinations.
Posaconazole and ketoconazole were first assessed at doses of up to 100 mg/kg by the
oral route in groups of two uninfected mice per dose. Posaconazole was tolerated at an
oral dose of 100 mg/kg/day for 5 days. One animal met euthanasia criteria in the group
given ketoconazole at 100 mg/kg/day for 5 days, but this drug was tolerated by both
mice at a dose of 50 mg/kg/day for 5 days.
Posaconazole and ketoconazole were evaluated in the murine visceral leishmaniasis
model reported on several occasions to test various compounds/formulations for
antileishmanial activity (4, 17, 18), including DB766 (2). According to the results of the
tolerability study outlined above, the highest dose of posaconazole administered was
100 mg/kg/day for 5 days, while the highest dose of ketoconazole given was 50
mg/kg/day for 5 days. Both azoles showed good activity in this model, with posacona-
zole and ketoconazole exhibiting ED50 values (the dose of the compound providing
50% reduction of the liver parasite burden compared to the positive-control group) of
21 mg/kg and 13 mg/kg, respectively (Fig. 3). No apparent drug-related adverse effects
FIG 2 In vitro evaluation of DB766-azole combinations against intracellular L. donovani. Posaconazole
(POS; gray bars), ketoconazole (KTC; horizontal striped bars), or fluconazole (FLC; diagonal striped bars)
was added to a serial dilution of DB766, with the azole at a fixed concentration, in at least three
independent experiments. The concentrations of azole drugs employed were below those required for
50% inhibition alone (parasite burden was reduced by 39%  3% at 6.3 M posaconazole alone [n  3],
23%  8% at 25 M ketoconazole alone [n  3], and 14%  5% at 50 M fluconazole alone [n  4]).
Error bars and measurements represent the standard errors of the means. Two-sided Student’s t test was
used to compare the groups to the DB766-alone group. **, P  0.01.
FIG 3 In vivo analysis of posaconazole and ketoconazole against L. donovani-infected BALB/c mice. Posaconazole
(POS) (A) and ketoconazole (KTC) (B) were given p.o. daily for 5 consecutive days to infected mice at the doses
indicated (in mg/kg). Results are shown as the percent reduction in LDU (Leishman-Donovan units) in liver tissue
versus untreated controls, with error bars representing the standard errors of the means.
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were observed in these studies, with the exception of one mouse in the 100-mg/kg
posaconazole group that met early removal criteria. At an oral dose of 10 mg/kg/day,
the miltefosine standard showed efficacy consistent with that observed previously
(4, 6).
Pharmacokinetics of DB766-posaconazole and DB766-ketoconazole combina-
tions. Effects of the partner drug on the pharmacokinetics of individual components of
DB766-posaconazole combinations were determined using healthy mice. The two
higher doses (50 and 100 mg/kg) of DB766 had little effect (15%) on the plasma
exposure (maximum plasma drug concentration [Cmax] and area under the concentration-
time curve [AUC]) of posaconazole (Table 1 and Fig. S4). Although the low dose (25
mg/kg) of DB766 appears to have increased the plasma exposure (by 50% for AUC) of
posaconazole, such an increase was presumed to be a result of intrinsic variability of
posaconazole pharmacokinetics at the high dose (100 mg/kg). In contrast, the two
higher doses (50 and 100 mg/kg) of posaconazole markedly increased the plasma
exposure (by up to 150% for Cmax and up to 100% for AUC) of DB766 (Table 1 and Fig.
S5). An in vitro metabolic stability study showed that microsomal half-lives of DB766
increased in the presence of posaconazole (see Table 3), suggesting an inhibitory effect
of posaconazole on DB766 metabolism. Hence, inhibition of DB766 metabolism by
posaconazole likely contributed to the decreased clearance and increased exposure to
DB766 observed in the mouse pharmacokinetic study.
Likewise, effects of the partner drug on the pharmacokinetics of individual compo-
nents of DB766-ketoconazole combinations were determined using healthy mice.
DB766 dose-dependently decreased the plasma Cmax (by 1.3- to 4.9-fold) of ketocona-
zole, and it also markedly decreased the plasma AUC (by 1.3- to 2.4-fold) of ketocona-
zole (Table 2 and Fig. S6). In contrast, the two higher doses (15 and 30 mg/kg) of
ketoconazole increased the plasma exposure (by up to 88% for Cmax and up to 68% for
AUC) of DB766 (Table 2 and Fig. S7). Metabolic stability study showed that microsomal
half-lives of DB766 increased in the presence of ketoconazole (Table 3), suggesting an
inhibitory effect of ketoconazole on DB766 metabolism. Hence, like posaconazole,
inhibition of DB766 metabolism by ketoconazole likely contributed to the decreased




Alone Combined with DB766 Alone Combined with posaconazole
Posaconazole dose, mg/kg (mol/kg) 25 (36) 50 (71) 100 (143) 25 (36) 50 (71) 100 (143) 0 0 0 100 (143) 50 (71) 25 (36)
DB766 dose, mg/kg (mol/kg) 0 0 0 100 (174) 50 (87) 25 (44) 25 (44) 50 (87) 100 (174) 25 (44) 50 (87) 100 (174)
Cmax, M 13  1 19  4 29  5 13  2 21  6 32  3 0.26  0.06 1.9  1.8 2.1  1.2 0.26  0.15 4.7  2 1.6  0.2
Tmax, h 12 12 12 12 24 24 2.0 0.5 2 1.0 1.0 2
AUC0-∞, M · h 392 698 858 437 802 1285 6.6 22 59 11 44 36
t1/2, h 11 9.6 8.4 11 9.3 11 30 25 26 33 36 29
CL/F, liter/h/kg 0.092 0.10 0.17 0.082 0.089 0.11 6.6 4.0 2.9 4.1 2.0 4.8
aAbbreviations: Cmax, maximum plasma concentration  standard deviations; Tmax, time to reach Cmax; AUC0-∞, area under the plasma concentration-time curve from
time zero to infinite time; t1/2, terminal elimination half-life; CL/F, apparent clearance without adjusting for bioavailability (F).




Alone Combined with DB766 Alone Combined with ketoconazole
Ketoconazole dose, mg/kg (mol/kg) 7.5 (14) 15 (28) 30 (56) 7.5 (14) 15 (28) 30 (56) 0 0 0 30 (56) 15 (28) 7.5 (14)
DB766 dose, mg/kg (mol/kg) 0 0 0 50 (87) 25 (44) 12.5 (22) 12.5 (22) 25 (44) 50 (87) 12.5 (22) 25 (44) 50 (87)
Cmax, M 0.74  0.41 1.8  0.8 4.5  1.7 0.15  0.03 1.2  0.8 3.5  1.4 0.08  0.04 0.25  0.1 1.2  0.9 0.15  0.04 0.37  0.3 0.82  0.3
Tmax, h 0.50 0.50 1.0 1.0 1.0 0.5 2.0 2.0 0.5 12 2.0 2
AUC0-∞, M · h 1.9 5.8 30 0.8 4.4 19 3.7 6.8 19 6.2 7.0 21
t1/2, h 1.7 1.8 3.6 1.7 1.7 2.8 25 24 26 24 25 29
CL/F, liter/h/kg 7.3 4.8 1.9 17 6.3 3.0 5.9 6.4 4.7 3.6 6.3 4.1
aAbbreviations: Cmax, maximum plasma concentration  standard deviations; Tmax, time to reach Cmax; AUC0-∞, area under the plasma concentration-time curve from
time zero to infinite time; t1/2, terminal elimination half-life; CL/F, apparent clearance without adjusting for bioavailability (F).
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clearance and increased exposure of DB766 observed in the mouse pharmacokinetic
study.
Efficacy of DB766-posaconazole and DB766-ketoconazole combinations in a
murine visceral leishmaniasis model. A checkerboard approach was used to evaluate
the efficacy of DB766-posaconazole combinations in L. donovani-infected BALB/c mice
in which three dose groups of the two compounds alone (DB766 at 75, 37.5, and 18.8
mg/kg/day for 5 days; posaconazole at 30, 15, and 7.5 mg/kg/day for 5 days) were
included to assess the efficacy of the monotherapies along with the nine different
combinations of these doses given to other groups of animals. Including the control
group, which received the polyethylene glycol 400 (PEG400) vehicle, 16 groups con-
taining four mice in each group were used in this combination study. The results of this
study are shown in Fig. 4. The ED50 value for DB766 alone in this experiment is 45
mg/kg, as calculated by Compusyn software, while the ED50 value of posaconazole
determined in this experiment is 27 mg/kg/day. In all cases, the DB766-posaconazole
combinations were more effective at reducing liver parasite burden than an equivalent
dose of either DB766 alone or posaconazole alone. Combination indexes (CIs) for each
combination group were also calculated with the aid of Compusyn. This method has
been used on numerous occasions to assess synergy between drug combinations
(19–22). CI values calculated for each combination enable a determination of the
interaction between individual components at each dose. For DB766-posaconazole
combinations, four of the groups showed synergism (CI, 0.30 to 0.70), two were
moderately synergistic (CI, 0.70 to 0.85), and three were nearly additive (CI, 0.90 to 1.10)
in the murine visceral leishmaniasis model according to the definitions for these effects
provided in earlier papers (19, 20).
TABLE 3 Metabolic stability of DB766 in mouse liver microsomes in the presence of an
azole as inhibitora
DB766 substrate (M) No inhibitor
Inhibitor
Posaconazole Ketoconazole
3 M 10 M 30 M 0.1 M 1 M 10 M
0.2 33 48 60 67 37 47 63
2 69 68 91 111 70 88 113
aMetabolic stability is measured as half-life, in minutes.
FIG 4 In vivo analysis of posaconazole-DB766 combinations in L. donovani-infected female BALB/c mice.
Compounds were given p.o. daily for five consecutive days to infected mice starting 1 week postinfection
in the presence of the indicated doses (in mg/kg/day) of DB766 (DB) and/or posaconazole (POS). Liver
smears were prepared 2 weeks postinfection, and parasite burden was determined microscopically.
Results are shown as the percent reduction of liver parasite burden versus the PEG400 control with error
bars representing the standard errors of the means.
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The approach described by Chou (20) was employed to examine the antileishmanial
efficacy of the DB766-ketoconazole combination (Fig. 5). According to this strategy, the
highest-combination dose contains a fraction of the maximum dose of each drug
administered alone (in this case, 0.6  0.6). Since the highest doses of DB766 and
ketoconazole administered alone were 75 mg/kg/day and 30 mg/kg/day, respectively,
the highest combination dose examined in this experiment was 45 mg/kg DB766 plus
18 mg/kg ketoconazole. The remaining doses for the combinations are also fractions of
the highest single doses of each drug at 0.4  0.4, 0.2  0.2, and 0.1  0.1. Similar ED50
values for both DB766 and ketoconazole were determined in this experiment compared
to those observed earlier (ED50 values of 34 mg/kg and 11 mg/kg, respectively) (Fig. 5).
However, only one of the DB766-ketoconazole combination groups showed synergism
(45 mg/kg DB766 plus 18.0 mg/kg ketoconazole; CI, 0.32), while the two intermediate-
dose groups displayed antagonism (30 mg/kg DB766 plus 12.0 mg/kg ketoconazole;
15.0 mg/kg DB766 plus 6.0 mg/kg ketoconazole; CI, 2.5 and 1.7, respectively). The
lowest-dose DB766-ketoconazole combination was nearly additive (CI, 0.97).
Liver concentrations of DB766 and posaconazole in L. donovani-infected
BALB/c mice. In an attempt to correlate the effectiveness of the DB766-posaconazole
combinations with the levels of compound in the target organ, liver concentrations of
both DB766 and posaconazole were determined at the end of the efficacy experiment
in L. donovani-infected mice. High concentrations of DB766 were observed in the liver
(Fig. 6A), consistent with earlier published results (2). There was a slight, but insignif-
icant, decrease in the liver concentration of DB766 when given at 75 mg/kg/day in the
presence of posaconazole at 7.5 or 15 mg/kg/day. For all other DB766-posaconazole
combinations, there was an increase in the DB766 concentration in the liver when
DB766 was administered with posaconazole that was statistically significant in two dose
groups. There were no decreases in posaconazole liver concentrations when this drug
was given together with DB766 compared to when this azole was given alone (Fig. 6B).
On the contrary, in all cases, posaconazole concentrations in the liver increased when
the drug was given together with DB766, although most were not statistically signifi-
cant due to the high variability (Fig. 6B). Table 4 provides a listing of efficacy, CI values,
and liver concentrations for each group receiving DB766 and/or posaconazole in this
experiment.
DISCUSSION
The interaction between azole drugs and other classes of compounds has been
examined in fungi and in kinetoplastid parasites. Several studies have demonstrated
FIG 5 In vivo analysis of ketoconazole-DB766 combinations in L. donovani-infected female BALB/c mice.
Compounds were given p.o. daily for five consecutive days to infected mice starting 1 week postinfection
in the presence of the indicated doses (mg/kg/day) of DB766 (DB; black bars) and/or ketoconazole (KTC;
gray bars). The combinations (horizontal striped bars) are given as a ratio of each of the highest doses
of ketoconazole and DB766. The miltefosine control group (white bar) received this compound at a dose
of 10 mg/kg/day for 5 days by the oral route. Liver parasite burden was determined, and results are
presented as described in the text.
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synergy between azoles and calcineurin inhibitors in fungi (23–26), while most of the
in vitro interactions between approved systemic antifungal drugs were indifferent when
assessed in three Candida species and two strains of Aspergillus fumigatus (27). In
Trypanosoma cruzi, combinations meeting the definition of in vitro synergy were not
always the most effective pairs in vivo (28). Interestingly, two combinations containing
posaconazole had superior efficacy compared to these drugs when administered alone
in a mouse model of T. cruzi infection (28). In vitro synergy has been described between
the squalene synthase inhibitor E5700 and both posaconazole and itraconazole against
intracellular L. amazonensis (29). We earlier reported in vitro synergy between DB766
and posaconazole in an intracellular assay using -lactamase-expressing L. donovani
parasites (7). However, the results described here, obtained from a high-content assay
using wild-type L. donovani parasites, indicates an additive or indifferent interaction
between these compounds. Despite the differences in the interactions observed be-
tween DB766 and posaconazole in the two intracellular studies, IC50s for DB766 and for
posaconazole were similar, although the current high-content assay more clearly
FIG 6 Tissue levels of DB766 (A) and posaconazole (B) in liver samples obtained from L. donovani-infected BALB/c mice.
Infected mice were treated with DB766, posaconazole, or DB766-posaconazole combinations as indicated in Fig. 4. At 2
weeks postinfection, liver samples from each animal were obtained and stored at 20°C or below prior to determination
of drug concentrations by UPLC-MS/MS. Symbols and error bars represent the means and standard errors of quadruplicate
determinations. One-way analysis of variance was used to compare treatments with combinations to drug alone (*, P 
0.05; **, P  0.01).
TABLE 4 Efficacy, CI values, and liver concentrations for groups in the DB766-











75 —c 69 — 168 —
37.5 — 40 — 21 —
18.8 — 23 — 6.3 —
— 30 57 — — 0.99
— 15 21 — — 0.59
— 7.5 6.5 — — 0.50
75 30 86 0.94 237 (1.4) 4.5 (4.6)
75 15 88 0.64 135 (0.80) 1.1 (1.9)*
75 7.5 75 0.94 147 (0.88) 1.1 (2.2)**
37.5 30 83 0.81 53 (2.5) 4.1 (4.2)
37.5 15 81 0.60 65 (3.1)* 1.2 (2.1)**
37.5 7.5 69 0.67 44 (2.1) 0.86 (1.7)
18.8 30 66 1.09 7.9 (1.3) 3.1 (3.2)
18.8 15 67 0.66 11 (1.8)* 0.84 (1.4)
18.8 7.5 49 0.72 7.3 (1.2) 0.52 (1.0)
aDoses are given in mg/kg/day administered by oral gavage.
bCalculated as the tissue concentration of the compound when given at the specified dose in combination
divided by the tissue concentration of the compound when administered alone at the same dose. *, P 
0.05; **, P  0.01.
c—, no value (e.g., when only one compound is given or when no CI value can be calculated).
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reveals the in vitro toxicity of posaconazole to peritoneal macrophages, as reflected by
a reduction in macrophage nuclei at higher azole concentrations. Ren et al. reported
that agreement rates for antifungal synergy testing were higher when MIC100 values
were used as endpoints rather than MIC50 values (27). Complete inhibition cannot be
used as an endpoint in these posaconazole/DB766 interaction experiments due to the
inability of posaconazole to clear parasites from macrophages in our hands. Differences
between the -lactamase and high-content assays and between the -lactamase-
expressing and wild-type parasites also may account for the difference in the interac-
tion between DB766 and posaconazole reported in the two studies. Unfortunately, the
original data for the -lactamase assays examining the DB766-posaconazole interaction
(7) are not available for comparison.
Both posaconazole and ketoconazole showed in vitro antileishmanial activity in the
present work as well as in other studies (29–31), while fluconazole had little effect on
Leishmania in vitro either in our hands or in previous reports (30, 32). Thus, the latter
drug was not considered for in vivo combination experiments. Results reported here are
consistent with the work of Al-Abdely et al., showing that posaconazole reduced liver
parasite burden by 0.5 to 1 log units in L. donovani-infected mice at an oral dose of 30
mg/kg given daily for 21 days (33). In female BALB/c mice infected with L. infantum,
ketoconazole had no observable effect on liver parasite burden but cleared the
infection from the spleen when given orally at 100 mg/kg/day for 11 days (34). The
calculated ED50 values in the present murine VL model for posaconazole (21 mg/kg/day
in Fig. 3A and 27 mg/kg/day in Fig. 4) and for ketoconazole (13 mg/kg/day in Fig. 3B
and 11 mg/kg/day in Fig. 5) are lower than the ED50 values for DB766 (Fig. 4 and 5 and
Wang et al. [2]). This is surprising given that DB766 is much more potent in the in vitro
antileishmanial assay in our hands than these azoles and also accumulates in the liver
(the target organ examined in our murine visceral leishmaniasis model) to a greater
extent than posaconazole in L. donovani-infected mice (Fig. 6). The reason for the
disconnect between in vitro and in vivo efficacy is unknown but may relate to the
mechanisms of action of these compounds, their possible effects on the host immune
system, and/or their potential distribution to different portions of the infected liver. The
effect exerted by posaconazole and ketoconazole on the parasites may provide an
explanation for the disconnect between the in vitro and in vivo antileishmanial activity
of these azoles observed in the present study. Azoles generally are regarded as having
a static antifungal effect on yeasts (35). In our intracellular L. donovani high-content
assay, there is little to no multiplication of the untreated control parasites within the
macrophages over the 72-h course of incubation with compounds (see Table S1 in the
supplemental material). This is generally consistent with previous observations in our
intracellular assay using -lactamase-expressing L. donovani, where modest prolifera-
tion was observed over the course of the infection (see Fig. 1 in reference 36). Thus, if
the azoles have a static effect on Leishmania, they may show modest activity in such an
assay. In the infected BALB/c mouse, however, L. donovani liver parasite burden
increases over the first month of infection (37), so a static azole compound may be
effective in this murine model.
Given that posaconazole is a known inhibitor of hepatic CYP3A4 (38) and increases
the microsomal half-life of DB766 (Table 3), inhibition of DB766 metabolism in mouse
liver may be responsible for the increased exposure of DB766 in the presence of this
azole. Ketoconazole is also a potent inhibitor of CYP3A4 but possesses activity against
other CYPs as well (39) and also prolongs the microsomal half-life of DB766 (Table 3).
While the highest dose of ketoconazole increased DB766 exposure, DB766 reduced
ketoconazole exposure (AUC and Cmax) by 22 to 80% (Table 2), perhaps due to
reduction of the oral absorption of ketoconazole by DB766. Based solely on these initial
pharmacokinetic experiments in uninfected mice, the posaconazole-DB766 combina-
tion would be predicted to be more effective than the ketoconazole-DB766 combina-
tion.
In the DB766-posaconazole combination study in the murine visceral leishmaniasis
model, the lowest CI value (0.60) was observed in mice receiving 37.5 mg/kg/day DB766
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and 15 mg/kg/day posaconazole. For this combination, there was an approximately
3-fold increase in the concentration of DB766 in the liver and about a 2-fold increase
in the liver concentration of posaconazole compared to levels for the corresponding
monotherapy dose groups; both of these increases were statistically significant (P 
0.05 and P  0.01, respectively). Other levels of synergy/moderate synergy (CI values of
0.64, 0.66, 0.67, 0.72, and 0.81) or indifference/additivity (CI values of 0.94, 0.94, and
1.09) were accompanied by either increases in the liver concentration of one or both of
the compounds compared to the levels for corresponding monotherapy groups or little
to no change in these liver concentrations. Thus, we hypothesize that the favorable
pharmacokinetics of the DB766/posaconazole combination, as observed in both unin-
fected animals (Table 1 and Fig. S3 and S4) and infected animals (Fig. 6, Table 4),
contributes to the antileishmanial synergy observed for this combination in the murine
visceral leishmaniasis model. In the DB766-ketoconazole study, only the highest dose of
the DB766-ketoconazole combination (DB766 at 45 mg/kg/day, ketoconazole at 18
mg/kg/day) showed a synergistic CI value (0.32), while the two intermediate doses of
the DB766-ketoconazole combination were antagonistic (CI, 1.5) and the lowest dose
was indifferent. At the high dose of ketoconazole administered to uninfected animals
(30 mg/kg), the AUC for DB766 increases by 68%, while lower doses of ketoconazole do
not result in comparable increases in DB766 AUC (Table 2). However, coadministration
of DB766 lowers the AUC and Cmax of ketoconazole (Table 2). Thus, these pharmaco-
kinetic studies in uninfected animals may help to explain the favorable interaction seen
between DB766 and ketoconazole at the highest dose of ketoconazole and the less
favorable interactions observed at lower doses. Unfortunately, the liver samples from
the DB766-ketoconazole combination efficacy study were unavailable for PK analysis
due to sample loss caused by a freezer failure.
Combinations of known antileishmanial drugs have shown excellent efficacy against
visceral leishmaniasis in clinical trials (40–42), but all of these combinations include at
least one injectable agent. Promising results also have been observed in rodent models
of visceral leishmaniasis with combinations of diminazene and chloroquine (43), milte-
fosine plus a liposomally encapsulated immunostimulatory oligonucleotide (44), and
antimony plus atovaquone (45), but these experimental combinations likewise contain
an injectable component. The work reported here explores oral combinations of the
frontrunner AIA DB766 with two orally available antifungal azoles possessing antileish-
manial activity and highlights the influence of pharmacokinetics on the efficacy of
these combinations. Given the efficacy of the DB766-posaconazole combination in the
murine visceral leishmaniasis model, further evaluation of this pair of agents in the
hamster model, which more closely mimics the progression of human VL, is warranted.
The use of CYP inhibitors in combination therapy in both HIV and HCV therapy argues
for the exploration of this approach against other infections; the CYP inhibitor in this
case (posaconazole) has the advantage of possessing in vivo antileishmanial activity in
its own right (Fig. 3A and 4). Furthermore, the present study contrasts the antileish-
manial properties of the frontrunner AIA DB766 with those of posaconazole and
ketoconazole. DB766 exhibits potent in vitro antileishmanial activity but lesser in vivo
efficacy than ketoconazole and posaconazole, which display lower antileishmanial
potency than DB766 in vitro. Thus, it may be useful to identify structural features that
are responsible for antileishmanial potency and favorable pharmacokinetics from both
classes of molecules as a strategy to discover new antileishmanial drug candidates.
MATERIALS AND METHODS
Parasites and culture conditions. Leishmania donovani LV82 promastigotes were cultured at 26°C
in Schneider’s insect medium (Life Technologies, Grand Island, NY) containing 25% heat-inactivated fetal
bovine serum (FBS; Sigma-Aldrich, St. Louis, MO), 50 U/ml penicillin, and 50 g/ml streptomycin (Life
Technologies). Experiments with these parasites were performed in accord with protocols approved by
The Ohio State University Institutional Biosafety Committee.
Drugs and reagents. Miltefosine was purchased from Cayman Chemical Company (Ann Arbor, MI).
Azoles were obtained from the following sources: ketoconazole was from TCI (Portland, OR), posacona-
zole was from Carbosynth (San Diego, CA), and fluconazole was from Cayman Chemical (Ann Arbor, MI).
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DB766 was synthesized as described previously (2). All other reagents were purchased from Sigma-
Aldrich unless otherwise stated.
In vitro susceptibility assays. An intracellular L. donovani high-content imaging assay was devel-
oped based on previously published methods (14, 15). Briefly, starch-elicited peritoneal macrophages
harvested from CD-1 mice were added to 96-well plates (Corning, Corning, NY) at a density of 1  105
macrophages/well in a total volume of 100 l macrophage medium (RPMI 1640 with GlutaMAX [Life
Technologies, Grand Island, NY], 10% heat-inactivated FBS [Sigma-Aldrich], 100 U/ml penicillin, and 100
g/ml streptomycin [Life Technologies], pH 7.4) and allowed to adhere overnight. The host cells then
were infected with stationary-phase L. donovani LV82 promastigotes at a parasite/macrophage ratio of
5:1 at 37°C in a 5% CO2 atmosphere. Extracellular parasites were removed by washing with Hanks’
balanced salt solution (HBSS; Life Technologies) after either 4 to 6 h or overnight incubation. In the case
where washing was performed after 4 to 6 h, fresh medium was added and incubation was continued
overnight. After the overnight incubation period in both cases, cells were washed with HBSS and fresh
medium containing either the compound(s) or the standard drug amphotericin B was added. Plates
again were placed at 37°C in a 5% CO2 atmosphere for an additional 72 h. Following this incubation,
plates were washed with phosphate-buffered saline (PBS) and fixed for 30 min in 10% formalin in PBS
(RICCA Chemical Company, Arlington, TX). After fixation, cells were washed with PBS, permeabilized with
0.1% Triton X-100 in PBS for 5 min, washed again in PBS, and stained with 2 g/ml 4=,6-diamidino-2-
phenylindole (DAPI; Life Technologies) in PBS for 10 min. After a final wash in PBS, 100 l of PBS was
added and plates were stored at 4°C prior to analysis. Images were acquired and analyzed using a
Thermo Scientific ArrayScan XTI live high-content platform (Thermo Fisher Scientific, Pittsburgh, PA).
In order to analyze these images, a standard DAPI filter set and the 20 lens standard on the Thermo
Scientific ArrayScan XTI was used to image 15 central fields of view from each well of stained samples
(each field, 485 by 485 m [1,104 by 1,104 pixels at 440 nm/pixel]) using an exposure time approximately
constraining pixel intensities to 4,000 gray levels (25% of the 14-bit range on the X1 charge-coupled-
device camera). Images were analyzed by the integrated SpotDetector V4 BioApplication algorithm.
Parasite nuclei (validated as 2 to 22 m2) were identified in annular (ring) regions of interest (ROIs)
originating one pixel outside the borders of a host cell nuclei (identified by a higher intensity threshold
than that for parasite nuclei and validated as 32 to 220 m2) and dilated isodiametrically to 50 pixels or
to collision with adjacently dilating ROIs (no ROI overlap). In sum, DNA puncta within 22 m of
presumptive host cell nuclei are ascribed to the nearest cell as an infection. Additional SpotDetector
parameters are available upon request.
IC50s (the concentration of the compound required to reduce the parasite burden by 50% compared
to infected controls) were calculated from the number of parasites per macrophage using the four-
parameter equation y  m1  (m2  m1)/[1  (x/m3)m4], determined by Kaleidagraph software (Synergy
Software, Reading, PA) to provide the relative IC50, where m1 is lower asymptote, m2 is upper asymptote,
m3 is relative IC50, and m4 is slope. This relative IC50 then was used to calculate the absolute IC50 using
the following equation: absolute IC50  exp(log(m3)  log((m2  m1)/(50  m1)  1)/m4). Absolute
IC50s are provided throughout the manuscript.
To determine the effect of combining DB766 with posaconazole in fixed-ratio dilutions (46), each
drug in a dilution series (drug A:drug B, 5:0, 4:1, 3:2, 2:3, 1:4, and 0:5) was used. The fractional inhibitory
concentration (FIC) for DB766 is defined as the IC50 of DB766 in combination/IC50 of DB766 alone. This
analysis was then repeated for posaconazole when an IC50 could be determined and the average sum of
the FICs was calculated. A mean 	FIC of 0.5 indicates a synergistic in vitro interaction, a mean 	FIC
between 0.5 and 4 indicates an indifferent interaction, and a mean 	FIC of 4 indicates antagonism (47).
To determine the effect of azoles on the DB766 IC50, the activity enhancement index (AEI) approach was
used (48). Serial dilutions of DB766 (the active compound) were plated with fixed concentrations of the
antifungal azole (the less active or inactive compound). IC50s for DB766 alone and DB766 in combination
were calculated as described above.
In vivo toxicity. In vivo toxicity and efficacy studies were performed in accord with protocols
approved by The Ohio State University IACUC. Six- to 8-week-old female BALB/c mice were given the
appropriate doses of single agent or combination therapy via oral gavage once daily for 5 days. The
overall appearance, weight, and activity of the animals were monitored, and any animals exhibiting
adverse effects due to compound administration were euthanized. All animals were euthanized 24 h after
the final dose and a gross necropsy was performed.
In vivo efficacy. Experiments in the murine visceral leishmaniasis model were performed as de-
scribed previously (17), with minor modifications. Briefly, BALB/c mice were inoculated with 5  107 L.
donovani promastigotes intravenously via the tail vein. After infection, mice were randomly sorted
(www.randomization.com; subjects randomized into 1 block) into groups of four and marked for
individual identification. Treatment began 7 days postinfection and continued once daily for 5 days.
DB766, posaconazole, and ketoconazole were suspended in PEG400 and given via oral gavage (p.o.).
Control groups received either PEG400 vehicle or miltefosine (10 mg/kg/day) dissolved in water. Mice
were euthanized on day 14 postinfection, livers were removed, and liver smear slides were prepared and
stained with Giemsa. The number of amastigotes per 100 cell nuclei were determined microscopically
and provided as Leishman-Donovan units (LDU). The following equation was used to calculate LDUs:
LDU  number of amastigotes per 1,000 cell nuclei  total liver weight in grams. To determine the
interactions between compounds used in combination, combination indexes were calculated using the
program Compusyn (ComboSyn, Inc., Paramus, NJ) (19).
Metabolic stability, pharmacokinetics, and tissue concentration. Metabolic stability of DB766 was
determined using mouse liver microsomes in the presence of different concentrations of posaconazole
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or ketoconazole. Microsomal incubations were carried out as described previously (2, 49). The mouse liver
microsomal protein concentration was 0.5 mg/ml. DB766 (as substrate) concentrations (0.2 and 2
M) and azole (as inhibitor) concentrations (3, 10, and 30 M for posaconazole; 0.1, 1, and 10 M for
ketoconazole) were selected to represent their maximal plasma concentrations in mice achieved
with doses tested in this study. Reactions were allowed to proceed for up to 60 min at 37°C and were
stopped with 2 volumes of 7:1 methanol-water containing 0.1% trifluoroacetic acid (vol/vol) and internal
standard. After centrifugation, the supernatant fractions were analyzed by high-performance liquid
chromatography-tandem mass spectrometry (HPLC-MS/MS) to quantify the amount of DB766 remaining
(2). Microsomal half-life (t1/2) values were obtained by fitting the one-phase exponential decay equation
(C  C0ekt; t1/2  0.693/k) to percent substrate remaining versus time curves.
To determine the effects of drug combination on the pharmacokinetics of the individual drug, the
single-dose pharmacokinetics of DB766 alone, azoles alone, and DB766-azole combinations were eval-
uated in uninfected male Swiss-Webster mice (in triplicate at each time point) after oral gavage. In vivo
pharmacokinetic studies were performed in accord with protocols approved by the University of Kansas
IACUC. DB766, posaconazole, and ketoconazole were dissolved in PEG400 as in the in vivo efficacy study.
The DB766 doses were 25, 50, and 100 mg/kg (or 43.5, 87.1, and 174 mol/kg). The posaconazole doses
were 25, 50, and 100 mg/kg (or 35.7, 71.3, and 143 mol/kg). The ketoconazole doses were 7.5, 15, and
30 mg/kg (or 14.1, 28.3, and 56.6 mol/kg). These doses were similar to those used in the efficacy studies
in BALB/c mice. The dose volume was 5 ml/kg, and no overt adverse effects were observed in mice at
these dose levels and in combinations tested. Blood sampling (
40 l per bleed) occurred 0.25, 0.5, 1,
2, 4, 8, 12, 24, 48, and 72 h postdose as described previously (50). Plasma was obtained by centrifugation.
Excised mouse liver samples were quickly rinsed with distilled water, blotted dry with tissue paper, and
weighed. All samples were stored at 20°C. Plasma and liver tissues were processed as described
previously (50) for quantification by HPLC-MS/MS.
The quantification of DB766, posaconazole, and ketoconazole was performed on a Waters Xevo TQ-S
triple-quadrupole mass spectrometer (Foster City, CA) coupled with a Waters Acquity ultraperformance
liquid chromatography (UPLC) I-class system. Analytical conditions for DB766 were described previously
in detail (2). The characteristic multiple reaction monitoring (MRM) transitions for posaconazole and
ketoconazole were m/z 701.3¡683.4 and 531.1¡82.1, respectively, under positive electrospray ioniza-
tion mode. Calibration curves for posaconazole and ketoconazole ranged from 0.025 to 25 M for plasma
samples and from 0.1 to 50 M for liver homogenate samples. The interday coefficient of variation and
accuracy were determined by measuring the same preparation of three standards three times on three
different days; deviations for all azoles were within 15%.
The area under the plasma concentration-time curve from time zero to the last time point (AUClast),
the area under the plasma concentration-time curve from time zero to time infinity (AUC0 –∞), terminal
elimination half-life (t1/2), maximum plasma drug concentration (Cmax), and time to reach Cmax (Tmax) were
calculated using the trapezoidal rule extrapolation method and noncompartmental methods (WinNonlin
version 6.4; Pharsight, Mountain View, CA).
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